论文部分内容阅读
目的：探讨三苯氧胺（tamoxifen，TAM）和甲孕酮（medroxyprogesteroneacetate，MPA）对人卵巢癌细胞增殖和凋亡的影响。方法：用不同浓度（0．1μmol／L、1μmol／L、10μmol／L）的TAM和MPA作用于人卵巢癌细胞系3A0，分别体外培养48h，72h，96h。用台盼蓝活细胞拒染法动态观察活细胞数，免疫组化法检测增殖细胞核抗原（proliferationcellnuclearantigen，PCNA）和表皮生长因子受体（epidermalgrowthfactorreceptor，EGFR）的表达情况，用DNA缺口原位末端标记方法检测细胞凋亡情况。结果：TAM和MPA在不同浓度均可使3AO活细胞数明显减少（P＜0．01），并呈时间依赖性；低浓度（≤1μmol／L）的TAM对PCNA表达的影响无统计学意义（P＞0．05），而高浓度（10μmol／U时可明显降低PCNA表达（P＜0．05）。不同浓度MPA均可使PCNA表达明显降低（P＜0．01）；TAM和MPA在各浓度均可显著抑制3AO细胞EGFR表达并促进凋亡发生（P＜0．01），且呈剂量依赖性，MPA诱导凋亡程度显著高于TAM（P＜0．01）。结论：TAM在低浓度时对卵巢癌细胞增殖抑制作用较弱，高浓度时不但可抑制卵巢癌细胞增殖，且可诱导细胞凋亡，但均弱于甲孕酮；TAM可用于卵巢癌的内分泌抗癌治疗，若疗效欠佳，仍可用MPA治疗。
Objective: To investigate the effects of tamoxifen (TAM) and medroxyprogesterone acetate (MPA) on the proliferation and apoptosis of human ovarian cancer cells. Methods: Human ovarian cancer cell line 3A0 was treated with different concentrations of TAM and MPA (0.1μmol / L, 1μmol / L, 10μmol / L) for 48h, 72h, 96h respectively. The number of viable cells was observed by trypan blue exclusion method. The expression of proliferating cell nuclear antigen (PCNA) and epidermal growth factor receptor (EGFR) was detected by immunohistochemistry. The expression of EGFR was detected by DNA nick end labeling Methods to detect apoptosis. Results: TAM and MPA could significantly reduce the number of living 3AO cells in a time-dependent manner (P <0.01), and the effect of TAM at low concentration (≤1μmol / L) on the expression of PCNA was not statistically significant (P> 0.05), but high concentration (10μmol / U) could significantly reduce the expression of PCNA (P <0.05) .The expression of PCNA was significantly decreased with different concentrations of MPA (P <0.01) (P <0.01) in a dose-dependent manner and the apoptosis induced by MPA was significantly higher than that of TAM (P <0.01) .Conclusion: TAM At low concentrations, the inhibitory effects on ovarian cancer cells were weaker than those at low concentrations, which not only inhibited the proliferation of ovarian cancer cells but also induced apoptosis, but both were weaker than that of progesterone. TAM could be used in endocrine anti-cancer therapy of ovarian cancer , If not effective, MPA treatment can still be used.